ErbB3, a possible prognostic factor of head and neck squamous cell carcinoma

Kim, Heejin; Choi, Joo Yeon; Rah, Yoon Chan; Ahn, Jung Yong; Kim, Hyunchul; Jeong, Woo Jin; Ahn, Sang‐Hyeon

doi:10.1016/j.oooo.2019.12.006

Cited by 4 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study performed on a large cohort of HNSCC patients, membranous ErbB3 overexpression was associated with worse overall survival and was significantly increased in metastatic lesions as compared to primary tumors ( 84 ). In different cohorts of HNSCC patients, ErbB3 expression levels have also been found to correlate with nodal stage, poor relapse-free, disease-free, and overall survival ( 68 , 85 , 86 ).…”

Section: Erbb Receptors and Prognosis Of Hnsccmentioning

confidence: 99%

Recent findings on the impact of ErbB receptors status on prognosis and therapy of head and neck squamous cell carcinoma

et al. 2023

View full text Add to dashboard Cite

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer type, has often an aggressive course and is poorly responsive to current therapeutic approaches, so that 5-year survival rates for patients diagnosed with advanced disease is lower than 50%. The Epidermal Growth Factor Receptor (EGFR) has emerged as an established oncogene in HNSCC. Indeed, although HNSCCs are a heterogeneous group of cancers which differ for histological, molecular and clinical features, EGFR is overexpressed or mutated in a percentage of cases up to about 90%. Moreover, aberrant expression of the other members of the ErbB receptor family, ErbB2, ErbB3 and ErbB4, has also been reported in variable proportions of HNSCCs. Therefore, an increased expression/activity of one or multiple ErbB receptors is found in the vast majority of patients with HNSCC. While aberrant ErbB signaling has long been known to play a critical role in tumor growth, angiogenesis, invasion, metastatization and resistance to therapy, more recent evidence has revealed its impact on other features of cancer cells’ biology, such as the ability to evade antitumor immunity. In this paper we will review recent findings on how ErbB receptors expression and activity, including that associated with non-canonical signaling mechanisms, impacts on prognosis and therapy of HNSCC.

show abstract

Section: Erbb Receptors and Prognosis Of Hnsccmentioning

confidence: 99%

Recent findings on the impact of ErbB receptors status on prognosis and therapy of head and neck squamous cell carcinoma

et al. 2023

View full text Add to dashboard Cite

show abstract

“… 159 , 160 High HER3 expression has been linked to disease progression and reduced survival in cancer patients, making it a potential target for therapy. 161 , 162 …”

Section: Therapeutic Trialsmentioning

confidence: 99%

Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies

He,

Zeng,

Wang

et al. 2024

MedComm

View full text Add to dashboard Cite

Antibody–drug conjugates (ADCs) consist of monoclonal antibodies that target tumor cells and cytotoxic drugs linked through linkers. By leveraging antibodies’ targeting properties, ADCs deliver cytotoxic drugs into tumor cells via endocytosis after identifying the tumor antigen. This precise method aims to kill tumor cells selectively while minimizing harm to normal cells, offering safe and effective therapeutic benefits. Recent years have seen significant progress in antitumor treatment with ADC development, providing patients with new and potent treatment options. With over 300 ADCs explored for various tumor indications and some already approved for clinical use, challenges such as resistance due to factors like antigen expression, ADC processing, and payload have emerged. This review aims to outline the history of ADC development, their structure, mechanism of action, recent composition advancements, target selection, completed and ongoing clinical trials, resistance mechanisms, and intervention strategies. Additionally, it will delve into the potential of ADCs with novel markers, linkers, payloads, and innovative action mechanisms to enhance cancer treatment options. The evolution of ADCs has also led to the emergence of combination therapy as a new therapeutic approach to improve drug efficacy.

show abstract

“…ErbB3 is a member of EGFR family of receptor tyrosine kinases, which serves as a homolog to EGFR (ErbB1) and HER2 (ErbB2) and plays an important role in cancers [13]. ErbB3 was upregulated in various cancers, such as breast cancer, gastric cancer, ovarian cancer, prostate cancer, bladder cancer, colon cancer, neck squamous cell carcinoma and melanoma [14][15][16][17][18][19][20][21][22][23][24]. Previous studies reported that the high level of ErbB3 and the activation of its downstream signaling including PI3K/AKT pathway and Ras/Raf pathway participated in the development and progression of cancers [25].…”

Section: Introductionmentioning

confidence: 99%

UHRF2 promotes Hepatocellular Carcinoma Progression by Upregulating ErbB3/Ras/Raf Signaling Pathway

Sun¹,

Wu²,

Chen³

et al. 2021

Int. J. Med. Sci.

View full text Add to dashboard Cite

Emerging evidence revealed that UHRF2 was implicated in a variety of human diseases, especially in cancer. However, the biological function, clinical significance and underly mechanisms of UHRF2 in hepatocellular carcinoma (HCC) is largely unknown. We analyzed the expression of UHRF2 in 371 HCC tissues and 50 para-cancerous tissues of TCGA database. We found that UHRF2 was significantly upregulated in HCC tissues, which was further confirmed in HCC cells and tissues by western blot. More importantly, the level of UHRF2 was correlated with pathological grade and clinical stage, and the patients with high level of UHRF2 had lower overall survival, disease-free survival and higher recurrence rate than those with low UHRF2 level. Univariate and multivariate Cox regression analysis revealed that high level of UHRF2 might be an independent prognostic factor for HCC patients. Functional investigations suggested that ectopic expression of UHRF2 could promote the proliferation, migration and invasion of HCC cell lines, whereas knock down of UHRF2 exhibited an opposite effect. Additionally, gene set enrichment analysis indicated that ERBB signaling pathway was upregulated in patients with high level of UHRF2. Pearson correlation analysis indicated that the expression of UHRF2 was positively correlated with ErbB3 and its downstream targets SOS1, Ras and Raf-1. Furthermore, we found that overexpression of UHRF2 could upregulate the expression of ErbB3, SOS1, Ras and Raf-1. Our findings suggested that UHRF2 might accelerate HCC progression by upregulating ErbB3/Ras/Raf signaling pathway and it might serve as a diagnostic marker and therapeutic target for HCC patients.

show abstract

ErbB3, a possible prognostic factor of head and neck squamous cell carcinoma

Cited by 4 publications

References 27 publications

Recent findings on the impact of ErbB receptors status on prognosis and therapy of head and neck squamous cell carcinoma

Recent findings on the impact of ErbB receptors status on prognosis and therapy of head and neck squamous cell carcinoma

Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies

UHRF2 promotes Hepatocellular Carcinoma Progression by Upregulating ErbB3/Ras/Raf Signaling Pathway

Contact Info

Product

Resources

About